Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline in Human Liver Transplantation
NCT02712775Phase 4
Key facts
- Status
- Withdrawn
- Start
- Mar 2016
- Primary completion
- Mar 2016
- Countries
- 1
- Sponsor
- Medical University of South Carolina
- Modality
- Small Molecules
- Drugs
- minocycline
- Conditions
- liver disease
01
Overview
Phase 4, randomised, double-blind trial in liver disease comparing Minocycline Arm with Placebo Arm (2 arms). Primary endpoint: Aspartate Aminotransferase at 6 months. Planned start Mar 2016; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Minocycline Arm
Experimental group receiving minocycline infusion and liver flush.
Placebo Arm
Control group receiving saline infusion and liver flush.
03
Who it enrols
Adult primary solitary orthotopic liver transplant recipients. Excludes pediatric, fulminant hepatic failure, split/living donor livers, multiple organ transplants, and re-transplant patients.
04
Endpoints
Primary
Aspartate Aminotransferase
Beyond the preview
Go deeper on NCT02712775.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712775.